Wound care company Uluru (OTCQB:ULUR) has created the “ideal wound product”, according to CEO Kerry Gray, with 2012 set to be a busy year for commercial milestones.
The company’s Altrazeal is a scientifically engineered product, which is based on Uluru’s
NanoFlex proprietary technology. It is a sterile powder that when
applied to a moist wound, interacts with bodily fluids and hydrates. The
NanoFlex powder then aggregates and creates a moist wound dressing that
conforms to the surface of the wound and seals it – helping to reduce
The result is an engineered advanced material designed to provide
specific properties to enhance healing and support tissue repair. The
dressing, which is composed of biocompatible materials used in several
medical devices, is a micro-porous, skin-like film that is intended as a
primary treatment for chronic wounds, such as leg ulcers, and diabetic
ulcers, and acute wounds, trauma and burns.
Altrazeal contours to mimic all wound sizes and shapes, and contains
68 percent water, which is almost equivalent to the skin – maintaining a
moist microenvironment, the company said.
Gray says the product’s vapour transportation rate, or the rate at
which the fluid from the wound is transported through the capillaries
into the atmosphere, is over 10 times greater than competitive items on
the market. This effectively manages fluid from the wound which allows
for extended recommended wear time of up to 10 days, and decreased
pressure at the wound bed – meaning support for cellular function and
The small pore size within the material also prevents bacterial
penetration and does not allow tissue to infiltrate, but does allow
oxygen to the wound.
A clinical study of 16 patients also showed a statistically
significant reduction in the amount of pain felt by patients when
compared to a leading product in the market. Patients have also reported
a “dramatic reduction in pain”, says Gray, when using Altrazeal on
venous leg ulcers or burns.
Gray recounts a patient that had a wound of 49 square inches for 27
years prior to using Altrazeal that over time, because of the pain
reduction, allowed for more and more compression therapy which is
necessary for healing. The wound was eventually healed.
The product is easy to remove by applying saline solution to the
material, then peeling it off “like a band-aid”. Gray says that the
extended wear time means less dressing changes as well as nursing
intervention in hospitals, providing for a cost-effective product.
Altrazeal is already approved in the US, Australia, New Zealand and
all throughout Europe – with the company set to market the product in
Australia, New Zealand and Germany later this year.
Gray says that markets such as Germany, Australia and New Zealand
are “extremely attractive” due to their emphasis on saving costs within
the health care system, which is a major product advantage of Altrazeal.
is also working with its existing licensee to secure the necessary
product approval in China – targeted for around mid-2012 – as well as
additional Asian markets where the CE Mark is accepted.
"Launching Altrazeal in China is a high priority as it is projected
that the Chinese market, which is currently approximately $25 billion,
will grow to $85 billion by 2013," says Gray.
product’s proven effectiveness in diabetic foot ulcers and venous
ulcers, the company is positioned to gain a significant share of the
large expanding wound segment.
Indeed, bolstering Altrazeal’s
international presence is important as the advanced wound care segment
of the global wound care market is estimated at $6.5 billion, said Uluru.
company is in ongoing talks with strategic partners to market the
product in the US, as well as in Canada and Mexico – where approval is
still necessary, but can be attained “quickly”, says Gray.
Plans are also in place for the launch of the wound care product in the near future into the veterinary market – where Novartis Animal Health is its worldwide partner.
adds that the company is looking to extend its product line with a
smaller 0.75 gram size of Altrazeal, reducing the price for smaller
wounds, and making it “more competitive” in the hospital market.
is a major advance in wound care, with a huge pharmacoeconomic benefit,
as it reduces nursing intervention and has the scientific properties to
enhance wound healing,” says Gray.
“It is an outstanding product, with the potential to save the health care system a lot of money.”
from Altrazeal, the specialty pharmaceutical company has a portfolio of
wound management and oral care products, including its
OraDisc B product for oral pain. The benzocaine disc provides a
controlled amount of local anesthetic to the covered area without
numbing the tongue and other parts of the oral cavity.
The company also has two FDA approved products, Aphthasol and OraDisc
A, for the prevention and treatment of canker sores. Meda the company’s
European partner is preparing to submit OraDisc A for approval in
has received its first European order for the launch of Altrazeal and
is in the process of making product for launch in seven different
markets, says Gray. The company’s stock closing price on March 31, 2012
was 25 cents.